-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BCD-180 in Ankylosing Spondylitis (Bekhterev’s Disease)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCD-180 in Ankylosing Spondylitis (Bekhterev's Disease) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCD-180 in Ankylosing Spondylitis (Bekhterev's Disease) Drug Details: BCD-180...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Bevacizumab Biosimilar in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bevacizumab Biosimilar in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bevacizumab Biosimilar in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab Biosimilar in Solid Tumor
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab Biosimilar in Solid Tumor report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab Biosimilar in Solid Tumor Drug Details: Pembrolizumab (Pembroria) is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pembrolizumab Biosimilar in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pembrolizumab Biosimilar in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pembrolizumab Biosimilar in Non-Small Cell Lung Cancer Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – BCD-245 in Neuroblastoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - BCD-245 in Neuroblastoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. BCD-245 in Neuroblastoma Drug Details: BCD-245 is under development for treatment of neuroblastoma....
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – ANB-10 in Hemophilia A (Factor VIII Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - ANB-10 in Hemophilia A (Factor VIII Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ANB-10 in Hemophilia A (Factor VIII Deficiency) Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – D3S-001 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - D3S-001 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. D3S-001 in Pancreatic Cancer Drug Details: D3S-001 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Levetiracetam ER in Mild Cognitive Impairment
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Levetiracetam ER in Mild Cognitive Impairment report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Levetiracetam ER in Mild Cognitive Impairment Drug Details: Levetiracetam ER...
-
Sector Analysis
Cell and Gene Therapies in Hemophilia A and B – Disease Overview, Treatment Options and Future Market Assessment
Cell and Gene Therapies (CGT) in Hemophilia A and B Market Report Overview The hemophilia A and B CGT market reached $12 million in 2023 with massive expansions across therapeutic areas. The CGT in Hemophilia A and B market research report will aid clients in gaining insight into the competitive landscape of leading CGT agents in Hemophilia A & B including launch date projections, key clinical trial analysis, analyst consensus forecasts, likelihood of approval analysis, and commentary on current and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Divozilimab in Neuromyelitis Optica (Devic’s Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Divozilimab in Neuromyelitis Optica (Devic's Syndrome) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Divozilimab in Neuromyelitis Optica (Devic's Syndrome) Drug Details: Divozilimab (Ivlizi)...